

## Index of Contributors

Alberini, C.M., 261-286  
 Alexandropoulos, K., 339-344  
 Apriletti, J.W., 366-389

Baltimore, D., 166-170, 339-344  
 Baxter, J.D., 366-389  
 Blake, D.J., 287-296  
 Bodmer, W., 414-426  
 Brinkmann, U., 345-354

Chambers, D.A., xiii-xiv, 1-11, 24, 171-173, 413, 441-458  
 Cheng, G., 339-344  
 Choy, L., 297-313  
 Cicchetti, P., 339-344  
 Crick, F.H.C., 198-199

Davidson, R.L., 355  
 Davies, K.E., 287-296  
 Doll, R., 329-330

Fitzgerald, D.J., 345-354  
 Fletterick, R.J., 366-389

Ghirardi, M., 261-286  
 Graves, R.A., 297-313

Heller, P., 86-96  
 Hood, L., 390-412  
 Hotchkiss, R.D., 55-73, 205-207  
 Huang, Y-Y., 261-286

Jackson, D.A., 356-365  
 Jacob, F., 218-223  
 Judson, H.F., 427-440

Kandel, E.R., 261-286  
 Klotz, I.M., 46-47  
 Klug, A., 143-160  
 Koop, B.F., 390-412

Lederberg, J., 176-179, 182-193

McCarty, M., 48-54

Nguyen, P.V., 261-286  
 Nichols, R.W., 174-175  
 Nirenberg, M., 224-242

Pai, L.H., 345-354  
 Pastan, I.H., 345-354

Ren, R., 339-344  
 Ribeiro, R.C.J., 366-389  
 Rich, A., 74-82, 97-142  
 Ross, S.R., 297-313  
 Rowen, L., 390-412

Schaufele, F., 366-389  
 Slavkin, H.C., 314-328  
 Solaro, R.J., 211-212  
 Selveva, V., 297-313  
 Spiegelman, B.M., 297-313  
 Stent, G.S., 25-31  
 Storti, R.V., 83-85

Temin, H.M., 161-165  
 Tickell, C., 180-181  
 Tinsley, J.M., 287-296  
 Tonegawa, S., 213-217

Wagner, R.L., 366-389

Walton of Detchant, Lord, 243-244

Watson, J.D., 194-197

Weatherall, D.J., 245-260

Weinberg, R.A., 331-338

West, B.L., 366-389

Wilkins, M.H.F., 200-204

## Subject Index\*

- A**  
 ADA deficiency. *See* Immunodeficiency  
 AIDS, 167, 320, 448. *See also* HIV; Retroviruses  
 Allergies, 415  
 Altman, R., 48  
 Altman, S., 183  
 Alzheimer's disease, 415, 424  
 Amelogenesis imperfecta, 314  
 Antisense RNA, 113-114  
 ApC/EBP. *See also* CCAAT enhancer-binding protein  
     cAMP-dependent expression of, 277-279  
     5-HT induction of, 272-277  
     and long-term facilitation, 267, 272-277  
 Aperiodic crystal of heredity, 25-31, 442  
 Arber, W., 360  
 Aristotle, 25, 28, 442  
 Astbury, W. T., 29, 198, 200, 443  
 Asthma, 415  
 Atheroma, 257  
*Aus meinem Leben*, 49  
 Austrian, R., 56, 68  
 Autoimmune diseases, 424  
 Avery, O. T., 5, 50, 61, 201. *See also* Avery-MacLeod-McCarty discovery  
 Avery-MacLeod-McCarty discovery  
     and aperiodic crystal, 442  
     and Avogadro's number, 4, 185  
     development of, 55-57  
     and DNA as language, 358  
     and genetic role of DNA, 26-27, 29, 48-54, 442  
     perspective on, 48-54  
     "premature discovery" of, 26-27  
     recognition of, 199  
     transforming principle as gene, 184  
**B**  
 Bacterial genetics, 66, 450. *See also* Molecular biology; Transformation  
 Bacterial viruses. *See* Phages  
 Baltimore, D., 21  
 Basic leucine zipper, 146-149, 446  
 Bateson, W., 46  
 Baxter, J., 19  
 Bayev, A., 80  
 Beadle, G., 218  
 Becker muscular dystrophy (BMD), 287-288.  
     *See also* Duchenne muscular dystrophy  
 Berg, P., 358  
 Bernal, J. D., 200, 425  
 Bernheimer, H., 68  
 Biological information. *See also* Human Genome Project  
     categories of, 390-391  
     deciphering chromosomal languages, 391-392  
     DNA as informational duplex, 190  
     T-cell receptor sequence analysis, 395-402  
 Biomedical revolution  
     DNA and molecular medicine. *See also* Biomedical science  
     and craniofacial-dental development, 453  
     gene therapy, 451-452  
     molecular mechanisms of behavior, 452  
     signal transduction in biological regulation, 452-453  
     single-gene diseases, 451  
     transgenic mice use in, 453  
 DNA/oncogenes/cancer  
     gene manipulation and, 455  
     multiple-step nature of cancer, 454  
     new cancer therapies, 455-456  
     nonreceptor kinases and, 454  
     double helix prospective, 457-458  
     and integrative biology, 450-451  
     pathway to double helix, 443-445  
     recombinant DNA and technology, 456-457. *See also* Human Genome Project  
 Biomedical science. *See also* Oral medicine; Recombinant DNA technology  
     double helix and, 182-183, 190-191  
     development of molecular genetics, 186-187  
     DNA as informational duplex, 187-190  
     historical background, 183-186  
     mechanistic interpretation and, 192  
 Biotechnology. *See* Recombinant DNA technology  
 Bodmer, W., 21  
 Boivin, A., 56  
 Boyer, H., 358, 360  
 Bragg, L., 428  
 Brenner, S., 7, 9, 36, 358  
**C**  
 CAMP  
     and implicit learning forms, 279-280  
     and long-term facilitation, 265-267, 270-271, 277-279  
     in short-term memory, 263

\* Page numbers in italics indicate photographs.

- cAMP response element (CRE)  
 in long-term facilitation, 267, 278  
 protein binding to, 267
- Cancer. *See also specific types*  
 adenovirus and, 334-335  
 genetic makeup and, 257  
 genome analysis and, 424  
 immunotherapy for, 329-330, 416  
 molecular basis of, 331-337  
 multistep process of, 331-332, 454  
 new therapeutic agents for, 345-346  
 oncogenes and, 332-334, 453-456  
 oral forms, 314  
 recombinant toxin therapy for, 329-330, 416  
 specific antiviral immunization and, 329-330  
 tumor suppressor genes and, 332-333
- Candida albicans* infection, 314  
 gene therapeutics for, 321, 323
- Caspar, D., 36
- Castle, W., 81, 91-93, 445
- Cavendish Laboratory, in molecular biology's golden age, 429, 431
- CCAAT enhancer-binding protein (C/EBP)  
 and *c-fos* regulation, 267  
 and long-term facilitation, 272-276
- C/EBP. *See* CCAAT enhancer-binding protein
- Cech, T., 183
- Cell in Development and Heredity, The*, 49
- Central dogma  
 of information flow, 188-189  
 process described, 83-85  
 reverse transcription in, 84-85  
 RNA-DNA relations in, 70  
 Temin's challenge to, 167  
 transformation studies and, 186  
 Watson's concept of, 7-8
- Cervical cancer, 329, 454
- Chambers, D., 208
- Chang, A., 360
- Chargaff, E., 4  
 appreciation of, 199  
 DNA analyses, 58, 60  
 and DNA nucleotide variety, 29  
 and nucleotide base ratios, 60-61, 185  
 overturn of tetranucleotide hypothesis, 442-443  
 "science makes the men," 30
- Chase, M., 7, 41. *See also* Hershey-Chase experiments
- Chemosensory deficiencies, 314
- Chloroplasts, DNA in, 118-119
- Chorionic somatomammotropin genes (hCS), 377-378
- Christmas disease, 256
- Chromatin, 46, 49
- Circuits. *See* Gene regulatory proteins
- Cohen, S., 358, 360
- Cold Spring Harbor Phage Group. *See* Phage Group
- Cold Spring Harbor Symposium for Quantitative Biology*, 1961, 220
- Colon cancer, 331-332
- Corey, R., 77, 121, 445
- Coryell, C., 76
- Cowan, P., 36
- Craniofacial-oral-dental anomalies. *See also* Oral medicine  
 congenital malformations, 314-319  
 craniofacial morphogenesis, 320  
 gene mapping of, 318-319
- Crawford, L., 43
- CRE. *See* cAMP response element
- CREB-like binding proteins  
 in implicit learning forms, 279-280  
 in long-term facilitation, 267, 272
- Crick, F. H. C., 2, 33, 34, 36, 43, 45  
 in 1953, 1  
 cooperative discovery of DNA, 198-199  
 and *The Double Helix*, 428  
 and  $\alpha$ -helix, 146  
 and language of DNA, 358  
 and molecular biology, 4, 7  
 and molecular biology's golden age, 430  
 and RNA double helix, 99
- Crothers, D. M., 358
- Cystic fibrosis, 256, 322
- Darlington, C. D., 200-201
- Darnell, J., 43
- Darwin, C., 26, 194
- Davies, D., 100
- Davies, K., 22
- Davis, R., 359
- Delbrück, M., 6, 9, 38, 39, 40  
 on biological specificity, 445  
 Bohr's influence on, 200  
 gene replication model, 69  
 gene stability hypothesis, 28  
 and intermolecular forces, 76  
 and molecular biology's golden age, 218, 429-431  
 and molecular genetics, 4, 28  
 and phage infection studies, 186  
 phage models for genetic studies, 442  
 Watson postdoc with, 99, 195
- Dental caries, 314, 321. *See also* Oral medicine
- Dentinogenesis imperfecta, 314
- Diabetes  
 evolution and, 257-258  
 obesity and, 304, 309-310  
 polygenic factors in, 258  
 transgenic mouse model for, 258

- DiGeorge syndrome, 314  
DMD. *See* Duchenne muscular dystrophy  
DNA. *See also* Central dogma; Gene(s); Nucleic acids  
as aperiodic crystal of heredity, 25-31, 442  
base pairing equivalence rule, 29  
and bioengineering tools, 9, 189-190  
and biotechnology. *See* Recombinant DNA technology  
and cancer, 329-330  
chemistry of, 58-64  
chromatography of hydrolysate bases, 58-61  
denaturability of, 61-64, 187-188  
discovery of, 1-2, 27, 48, 183  
DNA polymerase and, 102, 108  
DNase and, 52-54, 58, 417  
and drug discovery, 190  
duplex structure of, 182-183. *See also* DNA double helix  
and enzymology, 189  
and evolution, 188, 408, 410, 422-423  
four-stranded, 133-137  
and genetic code, 83-85  
and genetic linkage/recombination, 66-67  
as genetic material, 2, 27  
and Avogadro's number, 4, 185  
genetic role of. *See also* Avery-MacLeod-McCarty discovery; Hershey-Chase experiments  
acceptance of, 4, 7  
doubts about, 2, 4, 27-28  
perspective on, 48-54  
Phage Group and, 4, 28  
history of. *See also* Avery-MacLeod-McCarty discovery; Hershey-Chase experiments  
acceptance of central dogma, 186  
Fischer in, 49-50, 443  
historic papers, 13-17  
Miescher in, 27, 48, 183  
to 1954, 65  
phage experiments, 186  
hybridization of. *See* Hybridization  
as informational duplex. *See also* Human Genome Project  
central dogma and, 188-189  
in drug discovery, 190  
engineering tools and, 189-190  
and genetic relatedness, 188  
mutagenesis and repair and, 188  
reverse transcriptase and, 189  
separability of strands and, 187-188  
intraspecific polymorphism of, 188  
as a language, 358, 363-364  
and mechanistic interpretation, 192  
misconception about, 57  
and molecular biology, 7, 9, 83-85  
molecular/genetic study of, 68-69. *See also* Transformation  
and molecular medicine, 451-453  
mutagenesis and repair of, 188  
nature of genetic code, 83  
nucleotide content variability of, 29  
nucleotide equivalence rule, 2, 29  
in organelles, 118-119  
replication of, 83-84, 97, 107  
of retroviruses, 162-163  
RNA-dependent synthesis of, 167-168  
RNA involvement with, 58-60  
and RNA synthesis, 107-109  
sequencing projects, 456  
splicing, 189  
structure of. *See* DNA double helix  
synthesis of, 102, 108-109, 357, 446-448.  
*See also* Hybridization  
TATA-box and, 150, 272, 446  
transcription of, 143-145, 188-189  
and transformation questions, 57  
as transforming principle, 2, 48-54, 58-61  
triplex (H-DNA), 106  
in tRNA synthesis, 117-118  
viral single-stranded, 109  
DNA-binding domains  
hormone receptor, 150-153  
zinc-binding, 155-156  
zinc finger proteins in, 150-155  
DNA double helix  
acceptance of, 7  
at atomic resolution, 121-124  
bending mechanism, 133  
Chargaff's question about, 30  
concepts of, 182  
Conference sessions  
banquet, 448-449  
DNA and molecular medicine, 451-453  
DNA/oncogenes/cancer, 453-456  
DNA structure and synthesis, 446-448  
molecular/cellular/integrative biology, 449-451  
pathway to double helix, 443-445  
perspective, 442-443  
prospective, 457-458  
recombinant DNA and biotechnology, 456-457  
conformations of, 191-192  
discovery of, 1, 13-17  
*The Double Helix*, 30-31, 356, 427-431  
experimental data for, 1-2, 13-17  
gene evolution and, 447  
and gene regulation and morphogenesis, 191  
and genome mixing, 447  
and golden age of molecular biology, 429-432  
higher orders of organization in, 190-191

- implications of, 30  
 and life sciences transformation, 30  
 Lwoff and, 429-431  
 and medical diagnosis, 183  
 and molecular genetics, 357  
 pathway to, 443-446  
 perspective, 442-443  
 Phage Group and, 429-431  
 prospective, 457-458  
 questions raised by, 83  
 in retrospect, 427-439  
 reverse transcriptase and, 448  
 scientific ramifications of, 177-178  
 supercoiling of, 191  
 what follows, 98-100  
 X-ray crystallographic analyses of, 29  
 Z-DNA, 130-133, 191, 446  
 zinc fingers and, 446
- DNA revolution, 69-70
- Doty, P., 60, 117
- Double Helix, The*, 356  
 Chargaff review of, 30  
 Medawar review of, 31  
 reviews and responses to, 427-431
- Down's syndrome, 420
- Duchenne muscular dystrophy (DMD). *See also*  
 Becker muscular dystrophy  
 allelic BMD gene, 287-288  
 DMD locus genes, 289-290  
 dystrophin-associated glycoproteins and, 289  
 dystrophin gene and, 256, 288  
 dystrophin protein and, 288-289  
 first report of, 243  
 gene therapy strategies for, 291  
 linkage analysis of, 287-288  
 single-gene mouse model for, 319  
 utrophin and, 290-291, 452
- Dulbecco, R., 43, 166-167
- Dunitz, J., 97, 99
- Dyslexia, 415
- E**lectronic complementarity, 118-120
- Engelhardt, V., 80
- Enhancer response element (ERE), 267, 272-274, 277
- Ephrussi-Taylor, H., 56, 67-68, 70, 444
- Epidermal hyperplasia, 320
- ERE. *See* Enhancer response element
- Evolution  
 of biological information transfer and origin  
 of life, 112-114  
 RNA transcriptase in, 167-168  
 DNA-level polymorphism and, 188  
 gene mutation and, 26  
 and genetic diseases, 257-258  
 genetics and, 26  
 genome analysis and, 422-423  
 genomics and, 408  
 sequence analyses and, 410
- F**acilitation. *See also* Learning; Memory  
 5-HT in, 263-265  
 long-term  
 ApC/EBP and, 267, 272-277  
 cAMP-dependent gene expression and, 265-267  
 protein synthesis and, 265  
 phosphorylation cascade in, 263  
 protein/RNA synthesis and, 263-264
- Felsenfeld, G., 100
- First branchial arch syndromes, 314-315
- Fischer, E. O., 49-50, 443
- Flemming, W., 49
- Fox, M., 68
- Fragile X syndrome, 256-257, 415
- Franklin, R. E., 3  
 in 1953, 1  
 and B-pattern helix, 203  
 and DNA diffraction studies, 203  
 and DNA structure, 185  
 and molecular biology, 7  
 recognition of, 198  
 and two-chain helix interpretation, 30, 204  
 X-ray diffraction studies, 1-2  
 and X-ray equipment, 202
- Franklin-Gosling paper, 16-17, 441
- Fraser, B., 203
- G**arrod, A., 187
- Gene. *See also* DNA; Human Genome Project;  
 Oncogenes  
 Aristotle's notion of, 25, 28  
 for dyslexia, 415  
 for fragile X syndrome, 415  
 hCS, 377-378  
 hGH, 377-378  
 homeotic, 146  
 for Huntington's disease, 415  
 as information carrier, 28  
 linear genetic code, 28  
 long-term stability hypothesis, 28  
 for male sexual orientation, 415  
 nature of, 26-28  
 new description language for, 187  
 nucleoprotein nature of, 50  
 for partial deafness, 415  
 replication of, 97  
 stability of, 28  
 TR effects on, 377-378
- Gene expression. *See also* Gene regulatory proteins  
 biotechnology and, 107  
 cAMP-dependent, 265-267  
 in long-term memory, 263

- molecular biology and, 191  
multiple protein factors in, 143-144
- Gene mapping. *See also* Human Genome Project  
of craniofacial anomalies, 318-319
- Gene regulatory proteins  
basic leucine zipper, 146-149  
and circuits, 220-223  
DNA sequence recognition by, 144-145  
helix-turn-helix motif, 144-147  
homeobox proteins, 221, 224-226  
multiple protein factors in, 143-144  
operon model, 83-84, 143, 220-223  
protein-DNA interactions and, 144-145  
 $\beta$ -ribbon motifs, 149-150  
TATA-box binding proteins, 150, 272, 446  
zinc finger proteins, 150-156
- Gene targeting, 213-217
- Gene therapy. *See also* Recombinant DNA technology  
for DMD, 291  
genome analysis and, 415-417  
in hemoglobin disorders, 94  
in oral medicine, 322  
for xerostomia, 321, 323
- Genetic code  
and neurobiology, 224-237. *See also* Homeobox proteins; Homeotic genes  
research on, 450-451  
RNA and, 83-84  
transcription/translation of, 83-84  
transmission of, 83-84
- Genetic diseases. *See also* Craniofacial-oral-dental anomalies; Hemoglobin disorders;  
Molecular medicine  
evolutionary selection for, 257-258  
genotype/phenotype relationships and, 258  
phenotypic diversity of  
in human globin disorders, 246-255  
molecular basis for, 245-258  
in monogenic diseases, 255-256  
transgenic mouse models for, 297-310
- Genetic material. *See* DNA
- Genetic recombination, 66-67
- Genetics. *See also* Molecular genetics  
DNA genetics by 1954, 66  
and evolution, 26  
Mendel and, 26  
of retroviruses, 161-164  
rise of, 26-27
- Genome analysis. *See also* Human Genome Project  
and agriculture, 417  
and autoimmune diseases, 424  
conclusions about, 424-425  
and development and the brain, 419-420  
and disease genes, 414-415  
and evolution, 422-423  
and gene function, 418-419  
and gene sequence function, 417-418  
and gene therapy, 415-417  
and normal variation, 420-422  
and population studies, 422-423  
and technology, 417-418
- Genomics. *See also* Human Genome Project  
and biology, 408  
and chromosomal languages, 410  
and evolution, 410  
and languages of theoretical biology, 410  
motifs and, 408-409  
and regulatory code, 409-410
- Giacometti, G., 97
- Gilbert, W., 18, 20, 21, 80, 208  
DNA sequencing, 358  
and intron concept, 447  
and mRNA synthesis, 84  
Watson's view of, 195
- Gosling, R., 201-202. *See also* Franklin-Gosling paper
- Gouliau, M., 359
- Griffith, F., 2, 49, 54, 55, 184
- Haldane, J. B. S., 425
- Harker, D., 78
- hCS. *See* Chorionic somatomammotropin genes
- Heart disease, 257, 415
- $\alpha$ -Helix  
and DNA-binding proteins, 146-149  
Pauling and, 29, 47, 77  
zipper sequence and, 146
- Helix-turn-helix motif, 144-146
- Helling, R., 360
- Hemoglobin disorders. *See also* Sickle cell anemia; Thalassemia  
evolutionary selection and, 257  
Hb types, 91-93, 246-247, 253  
Pauling and, 81, 86, 89, 91-92, 445  
sickle cell hemoglobin  
discovery of, 88  
electrophoretic demonstration of, 92-93  
Hb types in, 91-93  
hypoxia and, 90-91
- Hemophilia, 256
- Heredity  
aperiodic crystal of, 25-31, 442  
theories of, 25-26
- Herpes simplex, 314, 321
- Hershey, A. D., 7, 41  
and linkage in bacteriophage, 67  
and phage group, 28-29  
reservations about DNA's role, 177
- Hershey-Chase experiments  
DNA as genetic material, 358, 444  
and "DNA-only" model, 186  
phage DNA as genetic material, 4, 7, 67-68  
phage in genetic studies, 442

- hGH. *See* Human growth hormone
- Hibernomas, 301-303
- Hippocrates, on heredity, 25
- HIV  
   in AIDS, 448  
   retroviral identity of, 167  
   in transgenic mouse line, 320  
   vaccine for, 416
- HIV infection, 314, 320
- Homeobox proteins, 221, 224-226, 226-228
- Homeodomains  
   helix-turn-helix motifs in, 144-146  
   in homeotic genes, 146  
   NK-2 domain, 226-227, 227
- Homeotic genes  
   homeodomain in, 146  
   NK-2 homeobox gene, 224-237  
   and transcription factors, 221
- Hood, L., 22
- Hotchkiss, R. D., 22, 40, 208  
   and bacterial genetics, 47  
   and DNA denaturability, 443  
   and pneumococcal transformation, 56-57  
   reflections on DNA revolution, 69-70  
   "The Night Before Crickmas," 205-207
- 5-HT. *See* Serotonin
- Human Genome Project. *See also* Biological information; Genome analysis; Molecular genetics  
   and craniofacial anomalies, 318-319  
   DNA as informational duplex and, 190  
   DNA revolution and, 198  
   and evolution of gene families, 456  
   major objective of, 391  
   and motifs, 408-409  
   Watson and, 390
- Hunter, A., 340
- Huntington's disease, 256-257, 415
- Hybridization  
   of DNA, 187-188  
   DNA-DNA, 111  
   and double helix RNA, 100-102  
   phage RNA-DNA, 117  
   RNA-DNA, 58, 109-112, 117
- Hypercholesterolemia, monogenic, 255
- Ikenberry, S., 208
- Immunodeficiency, severe combined, 322
- Immunotoxins  
   animal experiments with, 349-350  
   completely recombinant molecules of, 351-352  
   cytotoxic activity of, 348-349  
   future directions, 352-353  
   preclinical toxicology studies, 350-351  
   tissue culture experiments with, 347-349  
   tumor cell lines tested, 349
- Jackson, D., 23
- Jacob, F., 9, 20, 35, 37, 210  
   and *E. coli* Lac system, 219  
   and gene regulation, 83-84, 143  
   and molecular biology's golden age, 218
- Jacob-Monod operon model, 83-84, 220-223
- Jordan, P., 76
- Kaiser, D., 359
- Kandel, E., 22
- Kendrew, J., 29, 200, 218
- Khorana, H. G., 186, 358
- King, M., 78
- Klug, A., 83-84
- Kornberg, A.  
   DNA polymerase studies, 108  
   DNA synthesis/replication, 358-359  
   enzymic replication of DNA, 183, 186  
   paradigm shift statement, 364  
   and reverse transcriptase, 109
- Kossel, A., 48-49
- Krauss, M., 56
- Kuhn, T., 363-364
- Lacks, S., 68
- Learning. *See also* Memory  
   explicit forms of, 261-262  
   gene targeting studies of, 213-217  
   implicit forms of  
     cAMP-induced gene expression in, 279-280  
     CREB in, 279-280  
     and reflex systems, 261-264  
     sensitization of reflex response, 262-264  
     mechanisms in, 261-262, 280-281
- Lederberg, J., 23, 39, 208  
   and Avery paper, 27, 442  
   DNA and Avogadro's number, 4  
   and NYAS, 171
- Lehman, R., 359
- Levene, P. A., 49, 50, 184, 443
- Lipodystrophy, 309-310
- Lobban, P., 359
- Long-term potentiation (LTP)  
   induction of, 213  
   and learning and memory, 214-217  
   mossy fiber, 280-282  
   mossy fiber model, 282  
   Schaffer collateral, 280-281  
   synaptic facilitation mechanisms in, 280-281
- LTP. *See* Long-term potentiation
- Luria, S., 28-29, 38, 39, 43, 195-196, 218
- Lwoff, A., 37, 40, 43, 429-431
- MacArthur, I., 47
- MacLeod, C. M., 56, 68. *See also* Avery-MacLeod-McCarty
- Mandibulofacial dysostosis (MFD), 318-319

- Marmur, J., 60, 68  
 Marshak, A., 58  
 Mathews, A., 49, 443  
 Mazia, D., 70  
 McCarty, M., 19, 21, 52-54, 58. *See also* Avery-MacLeod-McCarty discovery  
 McClintock, B., 42, 69, 187  
 Medawar, P., 31, 443  
 Melanoma, 421  
 Memory. *See also* Learning  
   consolidation mechanism, 262  
   long-term, 262  
     and cAMP-mediated gene expression, 263  
     mRNA and, 262-264  
     and protein synthesis, 263  
   short-term, 262  
     and phosphorylation cascade, 263  
 Mendel, G., 25-27, 186, 442  
 Mertz, J., 359  
 Meselson, M., 9  
   and double helix replication, 70, 84  
   and genome mixing, 447  
   and molecular biology's golden age, 218  
   and mRNA synthesis, 84  
   and recombinant DNA technology, 360  
 Meselson-Stahl experiments, 70, 84  
 Messenger RNA (mRNA)  
   in central dogma, 83-84  
   concept of, 99, 113  
   in information flow, 188-189  
   isolation of, 111  
   and long-term memory, 262-264  
   in protein synthesis, 115-116, 143  
 Methemoglobinemia, 91. *See also* Hemoglobin disorders  
 MFD. *See* Mandibulofacial dysostosis  
 Microphthalmia, 319  
 Miescher, F., 27, 48, 183  
 Mirsky, A., 6  
   on Avery's discovery, 27  
   caution on Avery paper, 442  
   and protein structure, 445  
   protein structure theory, 76  
   skepticism about genetic material, 2, 4  
   and transforming principle as DNA, 53  
 Mitochondria, DNA in, 118-119  
 Molecular biology. *See also* Central dogma; Molecular genetics; Recombinant DNA technology  
   beginning of, 25  
   and cancer susceptibility, 453-454  
   circuits in higher organisms, 220-223  
   clinical roots of, 86-94  
   of cognition, 261  
     explicit learning mechanisms, 280-281  
     genetic mechanisms in, 281-283  
     implicit learning, 262-264  
     implicit learning mechanisms, 280-281  
     long-term facilitation, 265-280  
     major forms of learning, 261-262  
   consequences of, 9  
   control unit in bacteria, 220  
   and gene therapy, 93-94  
   golden age of, 218, 429-432  
   growth of, 9-10  
    $\alpha$ -helix and, 47  
   and neoplasia, 454  
   nuclear hormone receptors, 368-370  
   operon model, 220  
   pervasiveness of, 30  
   phage group and, 7, 28  
   of phenotypic diversity  
     in human globin disorders, 246-248  
     in other monogenic diseases, 255-256  
     in thalassemias, 248-255  
   regulatory circuit models, 220-223  
   scientist pairs in, 218-220  
   sickle cell hemoglobin and, 86-94  
   significance of, 10  
   structural transformations in  
     electronic publishing, 434-439  
     ethical problems, 432-434  
     exponential growth to steady state transition, 434-436  
   of thyroid hormone action. *See also* Thyroid hormone receptors  
     Watson-Crick and, 7  
*Molecular Biology of the Gene*, 9-10  
 Molecular disease, 81. *See also* Genetic disease  
 Molecular genetics. *See also* Molecular biology; Polymerase chain reaction; Recombinant DNA technology; Transgenic animals  
   Beadle-Tatum experiments and, 186  
   and biological sciences unification, 261  
   commercial enterprises using, 361-362  
   craniofacial anomalies gene mapping, 318-319  
   financial impact of, 363  
   flowering of, 186-187  
   human biochemical defects and, 187  
   recombination analysis in, 187  
 Monod, J., 37, 40. *See also* Jacob-Monod operon model  
   and *E. coli* Lac system, 219  
   and gene regulation, 83-84, 143  
   and molecular biology's golden age, 218  
 Morgan, T. H., 26, 75, 442, 445  
 Morrow, J., 360  
 mRNA. *See* Messenger RNA  
 Muller, H. J., 26-27, 188, 196  
 Mulligan, R., 21, 451  
 Mullis, K., 436  
 Muscular dystrophy, 322  
 Myopathies, 314  
 Myotonic dystrophy, 256

*Nature of the Chemical Bond, The*, 75Neurobiology. *See under* Genetic code

Nichols, R., 208, 210

Nirenberg, M., 20, 22, 358, 449-450

NK-2 homeobox gene

and CNS development, 450-451

distribution during development, 228-230, 233

expression of, 224-225

with developmental age, 228-237

by neuroblast/glioblast, 231-233, 236-237

pattern of, 233-236

homeodomain of, 227

nucleotide sequence of, 226-227

Nobel Laureates

in chemistry

Altman, S., 183

Berg, P., 358

Cech, T., 183

Fischer, E. O., 49

Gilbert, W., 18

Kendrew, J. C., 48

Klug, A., 83

Mullis, K., 436

Pauling, L., 78

Perutz, M., 77

Sanger, F., 358

Todd, A., 199

in physiology or medicine

Baltimore, D., 21

Beadle, G., 218

Cohen, S., 358

Crick, F. H. C., 2

Delbrück, M., 6

Dulbecco, R., 43

Hershey, A. D., 7

Jacob, F., 9

Khorana, H. G., 186

Kornberg, A., 167

Lederberg, J., 23

Luria, S., 38

Lwoff, A., 37

McClintock, B., 42

Medawar, P., 31

Monod, J., 37

Nirenberg, M., 20

Ochoa, S., 167

Tatum, E., 218

Temin, H., 167

Tonegawa, S., 22

Watson, J. D., 2

Wilkins, M. H. F., 3

Nuclear hormone receptors. *See also* Retinoic acid receptors; T-cell receptor families; Thyroid hormone receptors

function, 369-370

mechanism of action, 221

superfamily, 368-369

TR heterodimerization with, 374-375

Nucleic acids. *See also* DNA; RNA bases of

electronic complementarity of, 118-120

Hoogsteen-type pairing of, 104, 121, 124

Watson-Crick pairing, 121-124, 128, 130

X-ray analyses of, 121-122

DNA-RNA relations, 107-109

as genetic material, 50

early ideas about, 49-50

skepticism about, 46

hybridization of, 100-102

DNA strand-RNA strand, 109-112

Hoogsteen base pairing and, 104

and triple-stranded structure, 100-102

identification of sugars in, 49

Miescher's description of, 48

nucleotides and, 49

tetranucleotide hypothesis and, 50, 184

triple-stranded, 102-107

work on composition of, 48-49

*Nucleic Acids, The*, 61Nuclein. *See* Nucleic acids**O**besity

fat cell enhancer and, 299-300

genetic forms of, 298-300, 304

and hormonal secretion levels, 304

induction of, 304-309

as risk factor, 304, 309-310

transgenic animal models of, 297-300

Ochoa, S., 167

Oncogenes

Abl protein and, 339-343

adapter proteins and, 342-343

and cancer, 453-456

molecular basis of, 331

retrovirus vectors of, 164

tyrosine kinase and, 339-344

Operon. *See* Jacob-Monod operon modelOral medicine. *See also* Biomedical science; Recombinant DNA technology

animal models for human diseases, 319-321

biomaterials for, 321-322

conditions included, 314

craniofacial-oral-dental anomalies, 314, 316-319

gene therapy opportunities in, 315, 322

molecular approaches to, 314-316, 322

perspective, 315-316

prospective, 322-323

Orgel, Leslie, 33

Origin of life

Oparin's view, 112

reverse transcriptase and, 167-168

RNA and, 112-114

Osteoarthritis, 314

Osteoporosis, 314, 319, 321

- Pardee, A., 219  
Pastan, I., 19  
Paul, B., 43  
Pauling, A. H., 428  
Pauling, L., 78, 80. *See also* Sickle cell anemia  
    and antigen-antibody reactions, 76  
    and antioxidant vitamins, 81-82  
    appreciation of, 199  
    and biological molecules, 76  
    and chemical bond, 75  
    and chemical processes in biology, 75-76  
    and DNA structure, 185  
    and *The Double Helix*, 428  
    and enzyme action, 77, 79  
    and gene replication, 79  
    gene replication model, 69  
    and guanine-cytosine pairing, 121  
    and helical DNA structure, 203  
    and helical proteins, 202  
    and  $\alpha$ -helix discovery, 29, 47, 77, 202  
    and intermolecular forces, 76  
    and molecular evolution, 81  
    and molecular structure, 74-75  
    *The Nature of the Chemical Bond*, 75  
    Nobel Prizes, 75, 81  
    and  $\beta$ -pleated sheet structure, 77  
    and protein structure modeling, 29, 443-445  
    and protein structure theory, 76-77  
    on radiation damage, 81  
    Senate Internal Security Subcommittee and, 81  
    tribute to, 74-82  
    and triple-stranded DNA structure, 98  
    Watson-Crick debt to, 79  
PE. *See Pseudomonas* exotoxin A  
Periodontal diseases, 314, 321  
Perutz, M., 77, 200, 218  
*Phage and the Origins of Molecular Biology*, 430  
Phage Group, 9  
    and DNA's genetic role, 4  
    founding of, 28  
    and molecular biology, 7  
    Temin and, 166  
Phages  
    and DNA activity, 67-68  
    and gene replication, 28  
    as model systems, 4  
    transformation and, 67-68  
Pierre Robin syndrome, 314  
Pollock, M., 43  
Polymerase chain reaction (PCR). *See also* Molecular genetics  
    and entertainment industry, 362-363, 423  
    invention of, 435-436  
    and molecular biology, 189-190  
Polysomes, 114-117  
Pontecorvo, G., 43  
Poortman, Y., 44  
    "Premature discovery," 26-27, 176  
Protein kinases  
    and cancer, 340  
    in long-term facilitation, 265, 267, 271, 277-279  
    in LTP, 280-281  
    and oncogenes, 339-344  
    in short-term memory, 263  
Proteins. *See also* Gene regulatory proteins;  
    Homeobox proteins  
    Abl protein, 339-343  
    adaptor proteins, 342-343  
     $\alpha$ -helix structure of, 29, 47  
    specific DNA sequence recognition by, 144-145  
    synthesis of, 114-117  
    viewed as genetic material, 2, 27, 50, 184  
*Pseudomonas* exotoxin A (PE)  
    in cancer therapy, 346-347, 455  
    cytotoxic activity of, 347  
    endocytosis and, 347-348  
    as immunotoxin, 347  
Psychoses, 257  
Randall, J., 200-201  
Ravin, A., 68  
Recombinant DNA technology. *See also* Biomedical science; Molecular genetics  
    creation of, 359  
    development of, 360  
    *EcoRI* restriction enzyme and, 359-360  
    and gene regulation, 221  
    genetically engineered vaccines, 321  
    review of, 456-457  
    scientific disciplines using, 360-361  
    Watson-Crick model and, 356-357  
Regulatory proteins. *See* Gene regulatory proteins  
Retinitis pigmentosa, 319  
Retinoblastoma, 332-337, 454  
Retinoic acid receptors (RXRs), 318, 371-375.  
    *See also* Nuclear hormone receptors; T-cell receptor families; Thyroid hormone receptors  
Retroviruses. *See also* HIV; Rous sarcoma virus  
    in AIDS, 161, 448  
    DNA of, 162-163  
    genetics of, 161-164  
    in leukemia, 448  
    in mediated somatic gene therapy, 448  
    as oncogene vectors, 164  
    and reverse transcriptase, 161, 189  
    RNA of, 161-164  
Reverse transcriptase, 108-109  
    in evolution, 167-168  
    functions of, 161  
    and retroviruses, 161, 189  
    Temin and, 166-168

- Reverse transcription  
     and central dogma, 84-85  
     error rates in, 161, 163
- Rheumatic disease, 257, 314
- $\beta$ -Ribbons motifs, 149-150
- Ribosomal RNA (rRNA), 99
- Ribosomes, in protein synthesis. *See* Polysomes
- Rich, A., 22, 33, 36, 78, 80, 97, 208  
     and nucleic acid structure, 47  
     and protein structure, 47  
     and protein synthesis, 83-84  
     and RNA structure, 446  
     tRNA studies of, 83
- Rich, J., 97
- Rieger's syndrome, 314, 318
- RNA. *See also* Antisense RNA; Messenger RNA;  
     Ribosomal RNA; Transfer RNA  
     and DNA structure-function relationship, 7  
     double helix structure of, 100-102, 446  
     in genetic code transmission, 83-84  
     as genetic determinant, 70  
     misconception about, 57  
     molecular structure of, 99  
     and origin of life, 112-114  
     and protein synthesis, 107  
     of retroviruses, 161-164  
     synthesis of  
         DNA and, 107-109, 111-112  
         hybridization and, 100-102  
         and transformation, 58  
         triple-stranded, 102-107  
     X-ray diffraction study of, 100-101, 103-107
- RNA polymerase, 111, 113  
     activation of, 143
- Roberts, R., 360
- Rolfé, R., 9
- Rous sarcoma virus (RSV), 166-167, 455
- rRNA. *See* Ribosomal RNA
- RSV. *See* Rous sarcoma virus
- Ruben, H., 43
- Rubin, H., 166
- RXRs. *See* Retinoic acid receptors
- Ryan, F., 171, 173, 176
- Sachs, L., 43
- Sanger, F., 358
- Schizophrenia and depression, 420
- Schlenk, F., 46
- Schrödinger, E.  
     aperiodic crystal of heredity, 28-29  
     gene as information carrier, 28  
     genetic code concept, 442  
     *What Is Life?*, 28, 196, 442, 449
- Schultz, J., 50
- Science, public audience for, 70-72
- Scientific revolutions, 363-365
- Sensitization, 262-264. *See also* Learning
- Serotonin (5-HT)  
     and ApC/EBP induction, 272-277  
     and long-term facilitation, 265-271, 277-279  
     in pre-synaptic facilitation, 263-264
- Sgarbella, V., 359
- Sickle cell anemia, 445. *See also* Hemoglobin disorders  
     blood picture of, 87-88  
     chronology of developments in, 89  
     diagnostic test for, 89  
     gene therapy trials for, 322  
     hereditary nature of, 89-90  
     hypoxia and, 90-91  
     and selection against malaria, 257
- Siminovich, L., 40
- Slavkin, H., 21
- Smith, H., 360
- Snow, C. P., 425
- Sonneborn, T., 58, 196
- Spiegelman, S., 43
- Spinobulbar muscular atrophy, 256
- Stahl, F., 70, 218. *See also* Meselson-Stahl experiments
- Staker, M., 43
- Stent, G., 9, 21, 210  
     on double helix perspective, 442-443  
     in phage group, 24  
     and "premature discovery," 4, 56
- Stokes, A., 201-203. *See also* Wilkins-Stokes-Wilson paper
- Structure of Scientific Revolutions, The*, 363
- Sueoka, 60
- Sutherland, G., 78
- Szilard, L., 4, 41
- T<sub>3</sub>. *See* Thyroid hormone
- T<sub>4</sub>. *See* Thyroid hormone
- TATA-box binding protein, 150, 272, 446
- Tatum, E., 218
- Taylor, D., 201
- Taylor, H. *See* Ephrussi-Taylor
- T-cell receptor families. *See also* Nuclear hormone receptors; Retinoic acid receptors; Thyroid hormone receptors  
     genomics and, 390-392  
     human  $\beta$  T-cell receptor family, 403-408  
     sequence analysis of, 392-394, 403-405  
     non-TCR elements, 399  
     regulatory elements, 399-400  
     serendipity, 411  
     TCR elements, 395-399
- T-cell receptor loci  
     C $\delta$ C $\alpha$  region  
         conservation of, 395  
          $\alpha$  elements sequence analysis, 400-402  
         identifying receptor elements, 395-397  
         J $\alpha$  segments, 397-399

- non-T-cell receptor elements, 399  
regulatory elements, 399-400  
human  $\beta$  locus  
  chromosome translocation in, 403, 405  
  evolutionary comparisons of, 405-408  
  homology units, 403-404  
  sequence analysis of, 403-405  
  trypsinogen genes, 403
- Temin, H.  
  in memoriam, 166-170  
  and mutation-driven evolution, 448  
  and reverse transcriptase, 167-168  
  and reverse transcription, 84-85  
  and RSV, 166-167
- Tetranucleotide hypothesis, 50, 61, 184
- Thalassemia, 94. *See also* Hemoglobin disorders  
  evolutionary selection for, 257  
  heterogeneity of, 246-247, 255  
     $\alpha$ -thalassemia, 252-255  
     $\beta$ -thalassemia, 248-252  
  phenotypic diversity of  
    molecular basis of, 248-255  
     $\alpha$ -thalassemia, 252-255  
     $\beta$ -thalassemia, 248-252  
  selection against malaria, 257  
  single-gene mouse model for, 319
- Thomas, R., 68
- Thyroid hormone receptors (TRs). *See also*  
  Nuclear hormone receptors; Retinoic  
  acid receptors; T-cell receptor families  
  aspects of, 366-368  
  characteristics of, 370-371  
  and DNA conformation, 380  
  heterodimerization of, 374-375  
  and hGH/hCS, 377-378  
  and nuclear hormone receptors, 368-370,  
    374-375  
  properties of purified TRs, 371  
  recombinant overexpression of, 371-372  
  target gene recognition by, 372-374  
  three-dimensional TR-LBD structure, 382-  
    383  
  thyroid hormone-induced property changes  
    in, 380-382  
  transcription regulation by, 378-380
- Thyroid hormones ( $T_3$ ;  $T_4$ )  
  actions of, 456  
    on TR properties, 380-382  
    in vertebrate tissues, 367-368  
  forms of, 366-367
- Thyroid response elements (TREs), 368, 372-  
  376, 378-379, 382
- Tickell, C., 208, 210
- Todd, A., 199
- Tonegawa, S., 22, 449-450
- Transfer RNA (tRNA), 83-84  
  backbone of, 125-126  
  crystallization of, 124-125  
  high-resolution structure of, 126-129  
  in protein synthesis, 114, 116  
  structure of, 446  
  synthesis of, 117-118
- Transformation. *See also* Avery-MacLeod-McCarty  
  discovery  
    of *Bacillus subtilis*, 68  
  continuing thread of, 68-69  
  DNA as genetic information, 2  
  DNA chemistry and, 58-61  
  DNase experiments, 52-54  
  as genetic process, 63-67  
  growth after 1954, 68  
  of *Hemophilus*, 68  
  and phage, 67-68  
  and pneumococcal encapsulation, 56  
  questions about, 57-58  
  review of, 68-69  
  treatment of DNA extracts, 52
- Transforming principle, 27, 46, 48-54
- Transgenic animal models  
  adipose tissue types, 300-302  
  BAT culture line isolation, 303  
  with hibernomas, 300-303  
  for human oral disease, 319-321  
  for human viral diseases, 320  
  for obesity, 297-300, 453  
  obesity-resistant, 304-309  
  for retinoblastoma, 332-337, 454  
  uses for, 298  
  for Waardenburg syndrome type 1, 319  
  for X-linked cleft palate, 319
- Treacher Collins syndrome, 314
- Trigeminal neuralgia, 314
- tRNA. *See* Transfer RNA
- TRs. *See* Thyroid hormone receptors
- Tuberculosis, 416
- Tumor suppressor genes, 332-337
- Turner's syndrome, 243
- V**  
Vaccines, molecular biology and, 321, 416
- W**  
Waardenburg syndrome type 1, 319
- Watson, J. D., 2, 21, 23, 33, 34, 45, 97, 208,  
  209, 210, 357  
  in 1953, 1  
  and ApU structure, 124  
  at Caltech, 99  
  *The Double Helix*, 30  
  Hershey-Chase experiment influence on, 68  
  and Human Genome Project, 390  
  laboratory notebook entry, 7-8  
  and language of DNA, 358  
  meeting with Crick, 29  
  meeting with Wilkins, 29  
  and molecular biology, 7-9

- and molecular biology's golden age, 430  
Nobel Prize, 356-357  
and Pauling, 196  
personal reminiscence, 191-197  
and Phage Group, 28  
and RNA double helix, 99  
tribute to, 171  
Watson-Crick double helix. *See also* Central dogma  
1953 paper, 7, 13-14, 30-31, 121, 441  
base pairing in, 122-124, 128, 130  
and helical DNA structure, 203  
history of  
DNA as genetic material, 185-186  
nucleic acids discovery, 183  
protein chemistry developments, 184  
tetranucleotide theory, 184  
TMV crystallization, 184  
transformation studies, 184-185  
Hotchkiss and, 69-70  
modeling methods and, 79  
and molecular biology beginning, 25  
and mRNA concept, 99  
and recombinant DNA technology, 356-357  
and structure of DNA language, 358-359  
Weatherall, D., 22  
*What is Life?*, 28, 196, 442, 449  
Wilkins, M. H. F., 3, 78  
DNA at King's College, 200-204  
and DNA structure, 185  
and double helix, 30  
and *The Double Helix*, 428  
letter to Crick, 204  
and molecular biology, 7  
recognition of, 198  
and structure of DNA language, 358  
X-ray crystallographic analyses, 29  
X-ray diffraction studies, 1-2  
Wilkins-Stokes-Wilson paper, 14-16, 441  
Wilson, E. B., 49, 183-184, 443. *See also*  
Wilkins-Stokes-Wilson paper  
Wollman, E., 35, 219
- X**eroderma pigmentosum, 322  
Xerostomia, 314, 321, 323  
X-linked cleft palate, 319  
X-ray diffraction studies  
and DNA structure, 29  
of nucleic acids, 14-17, 98  
of RNA, 100-101
- Z**-DNA. *See* DNA double helix  
Zinc finger proteins, 446-447  
first class, 150-153  
hormone receptor DNA-binding domains,  
153-155  
other domains, 155-156  
Zipper. *See* Basic leucine zipper

